Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 2:06 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 313–336 of 10,802 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Developmental Defect Clear all
Not listed Phase 4 Interventional Accepts healthy volunteers

Liposomal Bupivacaine Versus Bupivacaine Plain for Operative Pain Management of Forefoot Surgery

NCT04751344
View directory record Official record
Conditions
Liposomal Bupivacaine, Postoperative Pain, Forefoot Surgery, Opioid Use, Bunion
Interventions
Liposomal bupivacaine, Bupivacaine HCl
Drug
Lead sponsor
Alexandra Black
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 25, 2021 · Synced Oct 23, 2026, 2:06 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Angioedema Biomarker Research Study

NCT06210698
View directory record Official record
Conditions
Angioedema, Angioedemas, Hereditary, Urticaria, Mastocytosis, ACE Inhibitor-Induced Angioedema, C1 Inhibitor Deficiency, Systemic Mastocytoses, Indolent Systemic Mastocytosis
Interventions
Venipuncture
Diagnostic Test
Lead sponsor
Foundation For Rare Disease Research
Other
Eligibility
12 Years to 75 Years
Enrollment
600 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Wheaton, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Oct 23, 2026, 2:06 PM EDT
Not listed Phase 3 Interventional

Comparative Effectiveness of Gadopiclenol for Evaluation of Adult Congenital Heart Anatomy and Hemodynamics

NCT06406517
View directory record Official record
Conditions
Congenital Heart Disease
Interventions
Gadopiclenol, Gadobenate dimeglumine
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated May 9, 2024 · Synced Oct 23, 2026, 2:06 PM EDT
Terminated Phase 2 Interventional Results available

An Efficacy and Safety Study of RPT193 in Adults With Atopic Dermatitis

NCT05399368
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
RPT193, Placebo
Drug · Other
Lead sponsor
RAPT Therapeutics, Inc., a member of the GSK plc group of companies
Industry
Eligibility
18 Years to 75 Years
Enrollment
229 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
56
States / cities
Birmingham, Alabama • Scottsdale, Arizona • North Little Rock, Arkansas + 45 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Oct 23, 2026, 2:06 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Exercise in Child Health

NCT05359991
View directory record Official record
Conditions
Cystic Fibrosis, Sickle Cell Disease, SARS CoV 2 Infection
Interventions
Exercise
Other
Lead sponsor
University of California, Irvine
Other
Eligibility
10 Years to 17 Years
Enrollment
240 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2027
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 23, 2026, 2:06 PM EDT
Completed Phase 2 Interventional

Safety, Pharmacokinetics and Pharmacodynamics of BPS804 in Osteogenesis Imperfecta

NCT01417091
View directory record Official record
Conditions
Osteogenesis Imperfecta
Interventions
BPS804
Drug
Lead sponsor
Ultragenyx Pharmaceutical Inc
Industry
Eligibility
18 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
2
States / cities
Anaheim, California • Miramar, Florida
Source: ClinicalTrials.gov public record
Updated May 11, 2021 · Synced Oct 23, 2026, 2:06 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Pilot Mouthwash Study of Pioglitazone and Simvastatin in Healthy Volunteers

NCT00531882
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Pioglitazone, Simvastatin, Ibuprofen
Drug
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
18 Years to 50 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
2
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 5, 2017 · Synced Oct 23, 2026, 2:06 PM EDT
Completed Phase 2 Interventional Results available

Study of Dupilumab and Immune Responses in Adults With Atopic Dermatitis (AD)

NCT02210780
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Dupilumab, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years to 64 Years
Enrollment
194 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
42
States / cities
Birmingham, Alabama • Fort Smith, Arkansas • Long Beach, California + 39 more
Source: ClinicalTrials.gov public record
Updated May 7, 2020 · Synced Oct 23, 2026, 2:06 PM EDT
Active, not recruiting Phase 3 Interventional

Study to Evaluate the Pharmacokinetics, Efficacy, Tolerability, and Safety of Subcutaneous Human Immunoglobulin (Newnorm) in Patients With Primary Immunodeficiency Diseases

NCT04640142
View directory record Official record
Conditions
Primary Immune Deficiency
Interventions
Newnorm
Biological
Lead sponsor
Octapharma
Industry
Eligibility
2 Years to 75 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
10
States / cities
Irvine, California • Centennial, Colorado • Port Saint Lucie, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Oct 23, 2026, 2:06 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

The NIH UNI Study: Urea Cycle Disorders, Nutrition and Immunity

NCT01421888
View directory record Official record
Conditions
Argininosuccinic Aciduria, Carbamoyl-Phosphate Synthase I Deficiency, Citrullinemia, Ornithine Carbamoyltransferase Deficiency, Hyperargininemia, N-Acetylglutamate Synthase Deficiency
Interventions
Not listed
Lead sponsor
National Human Genome Research Institute (NHGRI)
NIH
Eligibility
2 Years to 99 Years
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 9, 2019 · Synced Oct 23, 2026, 2:06 PM EDT
No Longer Available No phase listed Expanded access

Extension Study of Drisapersen in DMD Subjects

NCT02636686
View directory record Official record
Conditions
Duchenne Muscular Dystrophy
Interventions
Drisapersen
Drug
Lead sponsor
BioMarin Pharmaceutical
Industry
Eligibility
5 Years to 80 Years · Male only
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 24, 2018 · Synced Oct 23, 2026, 2:06 PM EDT
Completed Phase 2 Interventional Results available

RDEA3170 and Febuxostat Combination Study in Gout Subjects

NCT02246673
View directory record Official record
Conditions
Gout
Interventions
RDEA3170 15 mg, RDEA3170 10 mg, RDEA3170 2.5, RDEA3170 5 mg, Febuxostat 40 mg, Febuxostat 80 mg
Drug
Lead sponsor
Ardea Biosciences, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
6
States / cities
Anaheim, California • Glendale, California • South Miami, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2017 · Synced Oct 23, 2026, 2:06 PM EDT
Completed Phase 1 Interventional

Amyloid-related Imaging Abnormalities (Microbleeds) in Atypical AD

NCT01723553
View directory record Official record
Conditions
Atypical Alzheimers Disease, Logopenic Variant of Primary Progressive Aphasia (LPA), Posterior Cortical Atrophy (PCA)
Interventions
C-11 PiB
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 21, 2015 · Synced Oct 23, 2026, 2:06 PM EDT
Terminated Phase 2 Interventional Results available

A Study to Compare Vincristine to Sirolimus for Treatment of High Risk Vascular Tumors

NCT02110069
View directory record Official record
Conditions
Kaposiform Hemangioendothelioma (KHE), Kasabach-Merritt Syndrome, Tufted Angioma
Interventions
Vincristine, Sirolimus
Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
Up to 31 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
7
States / cities
Palo Alto, California • Atlanta, Georgia • Baltimore, Maryland + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2023 · Synced Oct 23, 2026, 2:06 PM EDT
Completed No phase listed Observational

23andMe IPF Research Study

NCT05028894
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
No intervention
Other
Lead sponsor
23andMe, Inc.
Industry
Eligibility
18 Years and older
Enrollment
690 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Sunnyvale, California
Source: ClinicalTrials.gov public record
Updated Dec 9, 2024 · Synced Oct 23, 2026, 2:06 PM EDT
Recruiting Phase 1 Interventional

Haploidentical Transplantation With Pre-Transplant Immunosuppressive Therapy for Patients With Sickle Cell Disease

NCT03279094
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Hematopoietic stem cell transplantation
Biological
Lead sponsor
City of Hope Medical Center
Other
Eligibility
1 Year to 30 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Oct 23, 2026, 2:06 PM EDT
Completed Phase 2 Interventional Results available

MK-3795 (PT2385) for the Treatment of Von Hippel-Lindau Disease-Associated Clear Cell Renal Cell Carcinoma (MK-3795-003)

NCT03108066
View directory record Official record
Conditions
VHL Gene Mutation, VHL, VHL Syndrome, VHL Gene Inactivation, Von Hippel, Von Hippel-Lindau Disease, Von Hippel's Disease, Von Hippel-Lindau Syndrome, Modifiers of, Clear Cell Renal Cell Carcinoma, Clear Cell RCC, ccRCC
Interventions
MK-3795
Drug
Lead sponsor
Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 24, 2024 · Synced Oct 23, 2026, 2:06 PM EDT
Active, not recruiting No phase listed Observational

Cardiopulmonary Outcomes in Osteogenesis Imperfecta: BBD7708

NCT05317637
View directory record Official record
Conditions
Osteogenesis Imperfecta
Interventions
Not listed
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years and older
Enrollment
18 participants
Timeline
2022 – 2027
U.S. locations
3
States / cities
Los Angeles, California • Baltimore, Maryland • New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced Oct 23, 2026, 2:06 PM EDT
Terminated No phase listed Observational

Death Following Congenital Heart Surgery

NCT00215072
View directory record Official record
Conditions
Congenital Heart Surgery, Congenital Heart Defects
Interventions
Not listed
Lead sponsor
Children's Healthcare of Atlanta
Other
Eligibility
Not listed
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 16, 2012 · Synced Oct 23, 2026, 2:06 PM EDT
Completed No phase listed Observational

Prognostic Value of Transforming Growth Factor-Beta 1 in Normal Pressure Hydrocephalus

NCT00600795
View directory record Official record
Conditions
Normal Pressure Hydrocephalus
Interventions
CSF collection
Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 4, 2017 · Synced Oct 23, 2026, 2:06 PM EDT
Completed Phase 3 Interventional Results available

Study to Assess the Safety and Tolerability of Idebenone in the Treatment of Friedreich's Ataxia Patients

NCT00697073
View directory record Official record
Conditions
Friedreich's Ataxia
Interventions
Idebenone
Drug
Lead sponsor
Santhera Pharmaceuticals
Industry
Eligibility
8 Years to 18 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
2
States / cities
Los Angeles, California • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 11, 2023 · Synced Oct 23, 2026, 2:06 PM EDT
Recruiting No phase listed Observational

A Study to Assess the Incidence of Skin Cancers in Patients With Epidermolysis Bullosa Receiving Filsuvez

NCT06423573
View directory record Official record
Conditions
Epidermolysis Bullosa, Dystrophic, Epidermolysis Bullosa, Junctional
Interventions
Filsuvez
Drug
Lead sponsor
Chiesi Farmaceutici S.p.A.
Industry
Eligibility
Not listed
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2032
U.S. locations
6
States / cities
Palo Alto, California • Aurora, Colorado • Gainesville, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 23, 2026, 2:06 PM EDT
Enrolling by invitation Phase 2 Interventional

Open-Label, Long-Term, Extension Study of Infigratinib in Children With Hypochondroplasia

NCT07393373
View directory record Official record
Conditions
Hypochondroplasia
Interventions
Infigratinib
Drug
Lead sponsor
QED Therapeutics, a BridgeBio company
Industry
Eligibility
3 Years to 18 Years
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2036
U.S. locations
8
States / cities
Oakland, California • Aurora, Colorado • Washington D.C., District of Columbia + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 23, 2026, 2:06 PM EDT
Completed Not applicable Interventional

Simulation-based Training for Nurses and Arteriovenous Fistula Puncture in Chronic Hemodialysis Patients

NCT05302505
View directory record Official record
Conditions
Nursing Caries, Arteriovenous Fistula, Simulation-based Training
Interventions
simulation-based training
Other
Lead sponsor
University Hospital, Caen
Other
Eligibility
18 Years and older
Enrollment
9,600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
0
States / cities
Not listed
Source: ClinicalTrials.gov public record
Updated May 1, 2026 · Synced Oct 23, 2026, 2:06 PM EDT